Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP4 | P49662 | 1/20 | 0.52 |
| ▸ | CASP5 | P51878 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | F2R | P25116 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25292161 | 0.95 | SIGMAR1 (0.54) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL30245440 | 0.95 | SIGMAR1 (0.54) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL30245062 | 0.92 | MAPT (0.55) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL25292330 | 0.92 | MAPT (0.55) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL30245820 | 0.91 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL25253539 | 0.91 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL25261366 | 0.90 | SIGMAR1 (0.59) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL30245758 | 0.90 | SIGMAR1 (0.63) | SIGMAR1ALDH1A1KDM4ECASP1CASP4 | |
| SCHEMBL30439022 | 0.90 | SIGMAR1 (0.59) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 | |
| SCHEMBL25295266 | 0.89 | MAPT (0.54) | SIGMAR1ALDH1A1KDM4EHRH3CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2024-10-31 | — | — | US | claimed |
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | claimed |
| WO-2023018472-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-02-16 | — | — | WO | claimed |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023018472-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | ITGB3, ITGA2, ITGAV | SIGMAR1 379/4885ALDH1A1 1217/4885KDM4E 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.